X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, AbbVie will advance Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action, which is anti-inflammatory and facilitates epithelial repair.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $212.5 million Upfront Cash: $137.5 million
Deal Type: Acquisition March 25, 2024
Details:
The collaboration aims to investigate the effects of NX-13, first-in-class, oral, gut-selective, NLRX1 agonist, on epithelial cells with the Inflammatory Bowel Disease.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: KU Leuven
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 14, 2023
Details:
NX-13 is a first-in-class novel, gut-selective oral therapeutic candidate that targets NLRX1 that has been associated with the modulation of inflammatory cytokines for UC and CD.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Landos Biopharma anticipates using the net proceeds from the investment to advance the development of NX-13 for Ulcerative Colitis and Crohn’s Disease and for other general corporate purposes.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.7 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 05, 2023
Details:
NX-13 is a novel, gut-restricted, orally active, small molecule therapeutic candidate for the treatment of UC. NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses.
Lead Product(s): NX-13
Therapeutic Area: Gastroenterology Product Name: NX-13
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
